Novartis | NOVN - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 33.67B 140M 2026-06
Alcon AG USD 6.62B 4M 2026-06
Almirall EUR 747.1M 33.12M 2026-06
Amgen USD 34.96B 3.49B 2026-06
AstraZeneca USD 31.45B 3.48B 2026-09
Autolus Therapeutics Ltd USD 336.09M 32.74M 2026-06
Bayer EUR 33.64B 1.66B 2026-06
Biogen USD 7.58B 278.7M 2026-09
Bristol-Myers Squibb USD 29.77B 1.19B 2026-09
Eli Lilly USD 65.26B 591M 2026-09
Fresenius EUR 11.61B 456M 2026-06
Fresenius Medical Care EUR 7.69B 418.66M 2026-06
Genmab DKK 2.8B 228M 2026-06
Gilead Sciences USD 16.55B 4.02B 2026-09
GlaxoSmithKline GBP 17.9B 336M 2026-09
GRIFOLS EUR 5.35B 40M 2026-09
Hikma Pharmaceutical USD 2.64B 86M 2025-12
J&J USD 56.35B 3.42B 2026-09
Lakefront Biotherapeutics EUR 2.31B 751.38M 2026-06
Lonza CHF 8B 3.41B 2025-12
Merck EUR 13.77B 393M 2026-06
Merck USD 36.68B 1.66B 2026-06
Novartis USD 28.75B 1.4B 2026-09
Novartis USD 28.75B 2.14B 2026-09
Novo Nordisk DKK 208.7B 31.38B 2026-06
Orion EUR 1.34B 139.5M 2026-09
Pfizer USD 45.01B 3.65B 2026-09
Philips EUR 9.33B 454M 2026-06
Recordati EUR 1.76B 29.78M 2026-06
Regeneron Pharmaceuticals USD 20.8B 2.35B 2026-09
Roche Holding CHF 35.44B 3.29B 2026-06
Sanofi EUR 33.21B 1.68B 2026-09
UCB EUR 6.05B 733M 2025-12